Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 65
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more

Conditions: Coronary Artery Disease, Pain, Postoperative
Interventions: Exparel, Placebo; Drug
Lead sponsor: Peter A Knight; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Anesthesia
Interventions: Placebo, Caffeine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 25 Years to 40 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid Abuse, Opioid Dependence
Interventions: buprenorphine, morphine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Erectile Dysfunction
Interventions: Platelet rich plasma, Placebo Sham Injection; Biological · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions: depot leuprolide acetate 3.75 mg, Placebo; Drug
Lead sponsor: Joseph Mccune; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Psoriasis
Interventions: Secukinumab, Placebo followed by Secukinumab; Drug
Lead sponsor: James G. Krueger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS-CoV-2 Infection, COVID-19, Maternal Immunization
Interventions: BNT162b2, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 726 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 56
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more

Conditions: Immunoglobulin A Nephropathy
Interventions: Povetacicept, Placebo (matched to Povetacicept); Drug
Lead sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 77
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Osteoarthritis
Interventions: onabotulinumtoxinA, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Artesia, California

Conditions: Traumatic Brain Injury
Interventions: 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 35
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Migraine Headache
Interventions: Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy; Drug · Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Athens, Ohio • Westerville, Ohio

Conditions: Dengue
Interventions: TetraVax-DV-TV005, rDEN3Δ30, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Safety, Pharmacokinetics, Healthy Subjects
Interventions: Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19 (Healthy Volunteers)
Interventions: CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more

Conditions: Healthy Volunteers
Interventions: KINE-101, Placebo; Drug
Lead sponsor: Kine Sciences Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis, Knee
Interventions: SI-613, Placebo; Combination Product
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Tucson, Arizona • Miami, Florida • Newton, Kansas + 6 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more

Conditions: Pain
Interventions: Ketorolac, Ibuprofen; Drug
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intracameral Antibiotics, Cataract Surgery, Phacoemulsification, Endophthalmitis, Vancomycin, Moxifloxacin
Interventions: Vancomycin, Moxifloxacin, Placebo; Drug
Lead sponsor: Panhandle Eye Group, LLP; Other
Eligibility: 30 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Age-Related Macular Degeneration
Interventions: Intravitreal aflibercept injection, Placebo; Drug
Lead sponsor: Jeffrey S Heier; Other
Eligibility: Not listed
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more

Conditions: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions: LV305, G305, LV305-matching placebo, G305-matching placebo; Biological · Other
Lead sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more

Search by objective public record fields.

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Parasternal Nerve Block in Cardiac Patients

A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

The Role of Platelet Rich Plasma for Erectile Dysfunction

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Safety and Efficacy of Secukinumab in Mild Psoriasis

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Drug and Non-Drug Treatment Of Severe Migraine

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

A First-in-Human Study of KINE-101 in Healthy Volunteers

SI-613 Study for Knee Osteoarthritis

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage

Intracameral Antibiotic Safety Study

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Investigating Dupilumab's Effect in Asthma by Genotype